Which of these patients should the nurse monitor closely for a potential risk for drug toxicity?

Choice A rationale

Administering omalizumab despite a reported allergy to peanuts is potentially unsafe because omalizumab has a black box warning for anaphylaxis, which can be life-threatening. While the peanut allergy may not directly contraindicate omalizumab, it suggests a heightened risk for severe allergic reactions due to atopy. Prudence dictates consulting the provider for risk assessment, skin testing, or alternative treatments, prioritizing patient safety before injection.

Choice B rationale

Omalizumab carries a risk of anaphylaxis, which can occur after any dose, including the first. A documented allergy, particularly to a common and potent allergen like peanuts, indicates a predisposition to hypersensitivity reactions (atopy). The most appropriate and safest nursing action is to withhold the injection and notify the healthcare provider to evaluate the risk and determine if the medication is still indicated or if precautions, such as desensitization or alternative therapy, are required.

Choice C rationale

Asking about recent anaphylaxis symptoms does not mitigate the potential risk of a future, severe reaction to omalizumab, which has a boxed warning for anaphylaxis. While a history of severe allergies is pertinent, the immediate safety concern is the risk of a severe hypersensitivity reaction to the drug itself. The nurse must address the reported allergy and the drug's known risks before proceeding with administration.

Choice D rationale

While ensuring an EpiPen is available is a precautionary measure for any patient receiving omalizumab due to the risk of anaphylaxis, it does not address the underlying concern of the documented peanut allergy, which might increase the patient's overall allergic predisposition. The nurse's first action must be to ensure the drug is safe to administer, which means consulting the provider about the allergy before administration.

Choice A rationale

Naloxone is an opioid receptor antagonist that competes with and displaces opioid molecules from μ-opioid receptors in the central nervous system. Its pharmacological action directly reverses the life-threatening effects of acute opioid overdose, primarily respiratory depression. It does not pharmacologically influence or immediately eliminate the patient's underlying drug-seeking behavior.

Choice B rationale

Opioid overdose causes respiratory depression and bradycardia (slowed heart rate), often below the normal range of 60-100 beats per minute. Naloxone reverses the respiratory depression, which then leads to improved oxygenation, and subsequent heart rate normalization (reversal of bradycardia). The primary immediate effect is reversing respiratory depression, which secondarily helps normalize the heart rate.

Choice C rationale

The rapid displacement of opioids by naloxone can precipitate an acute opioid withdrawal syndrome, characterized by symptoms like nausea, vomiting, sweating, and agitation. While this is a common consequence of administering the antagonist, the most immediate therapeutic goal in this life-threatening scenario is the reversal of inadequate ventilation to restore oxygenation and prevent hypoxia-related organ damage.

Choice D rationale

The most immediate life-threatening sign of opioid overdose is respiratory depression (patient's rate of 4 breaths per minute is dangerously low; normal is 12-20 breaths per minute), resulting from opioid binding to μ-receptors in the brainstem's respiratory centers. Naloxone rapidly reverses this central nervous system depression, stimulating the patient's drive to breathe, which is critical for restoring adequate oxygenation and ventilation.